Ocugen (OCGN) said Thursday that the first patient has been dosed in the phase 1 clinical trial of OCU200 for diabetic macular edema.
The trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in three cohorts, the biotechnology company said.
Ocugen said it plans to seek approval for OCU200 as a first-line therapy for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration.
Price: 0.72, Change: -0.01, Percent Change: -0.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.